AstraZeneca Signs License Deal with Alteogen for Subcutaneous Oncology Formulations
AstraZeneca and Alteogen Inc. have entered into an exclusive license agreement for ALT-B4, a novel hyaluronidase utilising Hybrozyme platform technology. Under the terms of the…
Read More...
Read More...